Skip to main content
Clinical Trials/NL-OMON40807
NL-OMON40807
Completed
N/A

HeartMate PHP CE Mark Clinical Investigation - HeartMate PHP

Thoratec Corporation0 sites10 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Coronary sclerosis
Sponsor
Thoratec Corporation
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Thoratec Corporation

Eligibility Criteria

Inclusion Criteria

  • \- At least 18 years of age.
  • \- Patient presents with a non\-emergent need for complex PCI with:
  • 1\) an ejection fraction of \<\=35% requiring hemodynamic support during the procedure,
  • 2\) the heart team has determined that the patient is not an optimal surgical candidate, OR the patient elects not to undergo surgery
  • \- Written, signed, and dated informed consent

Exclusion Criteria

  • \- Emergent PCI
  • \- ST elevation myocardial infarction within 7 days of procedure
  • \- Cardiac arrest within 7 days of procedure requiring CPR or defibrillation
  • \- Hemodynamic support with the HeartMate PHP post\-PCI is anticipated
  • \- Cardiogenic shock (SBP \<90 mmHg for \>1 hour with either cool clammy skin OR oliguria OR altered sensorium OR cardiac index \<2\.2 L/min/m2\)
  • \- Mural thrombus in the left ventricle
  • \- History of aortic valve replacement
  • \- Documented presence of aortic stenosis (orifice area of 1\.5 cm2 or less)
  • \- Moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as 2 or higher )
  • \- Severe peripheral vascular disease

Outcomes

Primary Outcomes

Not specified

Similar Trials